ECO-RESET: A Phase 2B, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Multicenter Study to Assess Efficacy and Safety of SER‑287 in Adults With Active Mild-to-Moderate Ulcerative Colitis
Phase of Trial: Phase II
Latest Information Update: 09 Jan 2019
At a glance
- Drugs SER 287 (Primary) ; Vancomycin
- Indications Ulcerative colitis
- Focus Registrational; Therapeutic Use
- Sponsors Seres Therapeutics
- 28 Nov 2018 Status changed from planning to recruiting.
- 28 Nov 2018 Planned number of patients changed from 200 to 201.
- 08 Nov 2018 According to a Seres Therapeutics media release, the company has designed this study as a potentially pivotal trial, and is awaiting feedback from the FDA on this final study design.